Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10	NOV 23	Addition of SCAN format to selected STN databases
NEWS 11	NOV 23	Annual Reload of IFI Databases
NEWS 12	DEC 01	FRFULL Content and Search Enhancements
NEWS 13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:44:46 ON 28 DEC 2009

=> File MEDLINE, SCISEARCH, LIFESCI, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'MEDLINE' ENTERED AT 14:44:58 ON 28 DEC 2009

FILE 'SCISEARCH' ENTERED AT 14:44:58 ON 28 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'LIFESCI' ENTERED AT 14:44:58 ON 28 DEC 2009
COPYRIGHT (C) 2009 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 14:44:58 ON 28 DEC 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:44:58 ON 28 DEC 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 14:44:58 ON 28 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 14:44:58 ON 28 DEC 2009
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2009)

FILE 'ESBIOBASE' ENTERED AT 14:44:58 ON 28 DEC 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 14:44:58 ON 28 DEC 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:44:58 ON 28 DEC 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> S (protease or proteinase or peptidase) (4A) (variant or mutant or mutated or mutation or mutating or mutagenesis or substitution or substitute or substituted or substituting or replace or replaced or replacing or replacement or exchange or exchanged or exchanging)
L1 14550 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (VARIANT OR MUTANT OR MUTATED OR MUTATION OR MUTATING OR MUTAGENESIS OR SUBSTITUTIO N OR SUBSTITUTE OR SUBSTITUTED OR SUBSTITUTING OR REPLACE OR REPLACED OR REPLACING OR REPLACEMENT OR EXCHANGE OR EXCHANGED OR EXCHANGING)

=> S (protease or proteinase or peptidase) (5A) (unexpected or unpredictable (3A) cleavage or cleaved or cleaving or cleave)
L2 15038 (PROTEASE OR PROTEINASE OR PEPTIDASE) (5A) (UNEXPECTED OR UNPRED ICTABLE (3A) CLEAVAGE OR CLEAVED OR CLEAVING OR CLEAVE)

```
=> S l1 (P) l2
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L7  (P) L18'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L9  (P) L20'
L3         386 L1 (P) L2

=> S (protease or proteinase or peptidase) (4A) (substrate binding)
L4         605 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (SUBSTRATE BINDING)

=> s l3 and l4
L5           0 L3 AND L4

=>
<------User Break------>

=> S (protease or proteinase or peptidase) (4A) (single substitution)
L6           8 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (SINGLE SUBSTITUTION)


=> S (protease or proteinase or peptidase) (5A) (unexpected or unpredictable (3A)
cleavage or cleaved or cleaving or cleave)
L7       15038 (PROTEASE OR PROTEINASE OR PEPTIDASE) (5A) (UNEXPECTED OR UNPRED
               ICTABLE (3A) CLEAVAGE OR CLEAVED OR CLEAVING OR CLEAVE)

=> s l6 and l7
L8           0 L6 AND L7

=> S (protease or proteinase or peptidase) (5A) (unexpected or unpredictable (3A)
cleavage or cleaved or cleaving or cleave)
L9       15038 (PROTEASE OR PROTEINASE OR PEPTIDASE) (5A) (UNEXPECTED OR UNPRED
               ICTABLE (3A) CLEAVAGE OR CLEAVED OR CLEAVING OR CLEAVE)

=> S (protease or proteinase or peptidase) (3A) (variant or mutant or mutated or
mutation or mutating or mutagenesis or substitution or substitute or substituted or
substituting or replace or replaced or replacing or replacement or exchange or
exchanged or exchanging)
L10      11665 (PROTEASE OR PROTEINASE OR PEPTIDASE) (3A) (VARIANT OR MUTANT
               OR MUTATED OR MUTATION OR MUTATING OR MUTAGENESIS OR SUBSTITUTIO
               N OR SUBSTITUTE OR SUBSTITUTED OR SUBSTITUTING OR REPLACE OR
               REPLACED OR REPLACING OR REPLACEMENT OR EXCHANGE OR EXCHANGED
               OR EXCHANGING)

=> S (protease or proteinase or peptidase) (4A) (unexpected or unpredictable (2A)
cleavage or cleaved or cleaving or cleave)
L11      13404 (PROTEASE OR PROTEINASE OR PEPTIDASE) (4A) (UNEXPECTED OR UNPRED
               ICTABLE (2A) CLEAVAGE OR CLEAVED OR CLEAVING OR CLEAVE)

=> s l10 and l11
L12        315 L10 AND L11

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l12
DUPLICATE PREFERENCE IS 'MEDLINE, SCISEARCH, LIFESCI, BIOSIS, EMBASE, HCAPLUS,
ESBIOBASE, BIOTECHNO, WPIDS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L12
L13         140 DUPLICATE REMOVE L12 (175 DUPLICATES REMOVED)
```

```
=> d l13 1-15 bib

L13  ANSWER 1 OF 140  WPIDS COPYRIGHT 2009       THOMSON REUTERS on STN
AN   2009-H28271 [30]   WPIDS
CR   2009-H49158; 2009-H50191
TI   Producing a stabilized, protease resistant apolipoprotein A1 (ApoA1)
     protein variant, comprises modifying the ApoA1 protein either by amino
     acid substitution or by chemical modification, and analyzing the
     proteolytic cleavage
DC   B04; D16; S03
IN   EYCKERMAN S; KAS K; LABEUR C
PA   (PRON-N) PRONOTA NV
CYC  122
PIA  WO 2009050275   A1 20090423 (200930)* EN  43[3]
ADT  WO 2009050275 A1 WO 2008-EP64054 20081017
PRAI EP 2007-118859       20071019

L13  ANSWER 2 OF 140  WPIDS COPYRIGHT 2009       THOMSON REUTERS on STN
AN   2009-F31009 [18]   WPIDS
CR   2009-F36129; 2009-M04592
TI   Modified polypeptide capable of lysing bacterial cell walls, useful as a
     medicament or diagnostic agent, has amino acid substitutions at protease
     cleavage sites that inhibit degradation by proteases
DC   B04; D13; D16; D21
IN   FORCHHEIM M; GRALLERT H
PA   (PROF-N) PROFOS AG
CYC  122
PIA  WO 2009024142   A2 20090226 (200918)* DE  50[12]
     WO 2009024142   A3 20090618 (200940)  EN
     DE 102007061929 A1 20090625 (200942)  DE
ADT  WO 2009024142 A2 WO 2008-DE1378 20080819; WO 2009024142 A3 WO 2008-DE1378
     20080819; DE 102007061929 A1 DE 2007-102007061929 20071221
PRAI US 2007-957351P      20070822
     EP 2007-114785       20070822
     DE 2007-102007061929 20071221
     US 2008-32211P       20080228
     EP 2008-152096       20080228
     DE 2008-102008023448 20080514

L13  ANSWER 3 OF 140  WPIDS COPYRIGHT 2009       THOMSON REUTERS on STN
AN   2009-F15981 [16]   WPIDS
CR   2009-M96375; 2009-Q46329
TI   New composition comprises an antigen and a heterologous hepatitis C virus
     (HCV) NS3 protease cleavage site, useful for enhancing an immune response
     to a hepatitis C antigen and for treating and preventing HCV infection
DC   B04; C06; D16
IN   FRELIN L; SALLBERG M; SODERHOLM J; FELIN L
PA   (TRIP-N) TRIPEP AB
CYC  122
PIA  WO 2009022236   A2 20090219 (200916)* EN  278[24]
     US 20090074803  A1 20090319 (200921)  EN
     WO 2009022236   A8 20091001 (200964)  EN
ADT  WO 2009022236 A2 WO 2008-IB3047 20080815; US 20090074803 A1 Provisional US
     2007-956326P 20070816; US 20090074803 A1 Provisional US 2008-47076P
     20080422; US 20090074803 A1 US 2008-192776 20080815; WO 2009022236 A8 WO
     2008-IB3047 20080815
PRAI US 2007-956326P      20070816
     US 2008-47076P       20080422
     US 2008-192776       20080815

L13  ANSWER 4 OF 140     MEDLINE on STN                DUPLICATE 1
```

AN 2009671757 IN-PROCESS
DN PubMed ID: 19556225
TI Insights into the enzyme-substrate interaction in the norovirus 3C-like protease.
AU Someya Yuichi; Takeda Naokazu
CS Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashi-Murayama, Tokyo 208-0011, Japan.. someya@nih.go.jp
SO Journal of biochemistry, (2009 Oct) Vol. 146, No. 4, pp. 509-21. Electronic Publication: 2009-06-24. Journal code: 0376600. E-ISSN: 1756-2651. L-ISSN: 0021-924X.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 8 Oct 2009
Last Updated on STN: 16 Dec 2009

L13 ANSWER 5 OF 140 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:163673 HCAPLUS
DN 148:231729
TI Methods for engineering and synthesis of single-chain, activatable Clostridial neurotoxins comprising a functional binding domain, translocation domain, therapeutic element and exogenous protease cleavage site for use in therapy
IN Steward, Lance E.; Francis, Joseph; Fernandez-Salas, Ester; Gilmore, Marcella A.; Li, Shengwen; Dolly, J. Oliver; Aoki, Kei Roger
PA Allergan, Inc., USA
SO U.S. Pat. Appl. Publ., 169pp., Cont.-in-part of U.S. Ser. No. 326,265. CODEN: USXXCO
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080032930	A1	20080207	US 2007-832173	20070801
	EP 1700918	A2	20060913	EP 2006-2253	20000825
	EP 1700918	A3	20070905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 7132259	B1	20061107	US 2000-648692	20000825
	US 20060099672	A1	20060511	US 2006-326265	20060105
	US 7419676	B2	20080902		
	US 20070259401	A1	20071108	US 2006-610440	20061213
	US 7422877	B2	20080909		
	US 20080081355	A1	20080403	US 2007-782112	20070724
	US 20080161226	A1	20080703	US 2007-845167	20070827
	US 20080221012	A1	20080911	US 2007-845252	20070827
	US 20080182294	A1	20080731	US 2007-926812	20071029
	US 20090087458	A1	20090402	US 2008-177415	20080722
	US 20080311622	A1	20081218	US 2008-182801	20080730
	US 20090005313	A1	20090101	US 2008-192419	20080815
	US 20090069238	A1	20090312	US 2008-192900	20080815
	US 20090081730	A1	20090326	US 2008-193527	20080818
	US 20090030188	A1	20090129	US 2008-195985	20080821
	US 20090030182	A1	20090129	US 2008-196658	20080822
	US 20090042270	A1	20090212	US 2008-196381	20080822
PRAI	US 1999-150710P	P	19990825		
	US 2000-648692	A3	20000825		
	US 2006-326265	A2	20060105		
	EP 2000-964920	A3	20000825		

US 2006-610440 A1 20061213
US 2007-782112 A1 20070724
US 2007-829475 B1 20070727
US 2007-832173 A1 20070801
US 2007-833720 B1 20070803
US 2007-844899 B1 20070824
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L13 ANSWER 6 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2008-O20672 [82] WPIDS
DNC C2008-457043 [82]
DNN N2009-048400 [82]
TI New computer system comprises directed by software correlating the presence of mutation in HIV-1 protease cleavage sites in the gag region, useful for evaluating the effectiveness of a protease inhibitor as an antiviral therapy against HIV
DC B04; D16; S03; T01
IN DE MEYER S; DIERYNCK I
PA (TIBO-N) TIBOTEC PHARM LTD
CYC 121
PIA WO 2008145606 A1 20081204 (200882)* EN 20[0]
AU 2008257703 A1 20081204 (200978) EN
ADT WO 2008145606 A1 WO 2008-EP56356 20080523; AU 2008257703 A1 AU 2008-257703 20080523
FDT AU 2008257703 A1 Based on WO 2008145606 A
PRAI EP 2007-108899 20070525

L13 ANSWER 7 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2008-M32158 [72] WPIDS
DNC C2008-376721 [72]
DNN N2008-906996 [72]
TI Identifying modified proteases with modified substrate specificity or other properties by contacting a collection of proteases with a protease trap polypeptide and identifying or selecting a protease
DC B04; D16; S03
IN MADISON E L; MADISON E
PA (CATA-N) CATALYST BIOSCIENCES INC; (TORR-N) TORREY PINES INST MOLECULAR STUDIES; (MADI-I) MADISON E L
CYC 122
PIA WO 2008045148 A2 20080417 (200872)* EN 257[1]
WO 2008045148 A3 20081016 (200872) EN
WO 2008045148 A8 20080904 (200872) EN
WO 2008045148 A9 20080529 (200872) EN
TW 2008017517 A 20080416 (200921) ZH
EP 2046951 A2 20090415 (200926) EN
KR 2009031936 A 20090330 (200927) KO
NO 2008005408 A 20090406 (200931) NO
US 20090123452 A1 20090514 (200933) EN
IN 2009CN00541 P4 20090605 (200951) EN
AU 2007307260 A1 20080417 (200952) EN
CA 2656531 A1 20080417 (200953) EN
CN 101517074 A 20090826 (200959) ZH
MX 2008016221 A1 20090228 (200962) ES
JP 2009542218 W 20091203 (200979) JA 225
ADT WO 2008045148 A2 WO 2007-US15571 20070705; US 20090123452 A1 Provisional US 2006-818804P 20060705; US 20090123452 A1 Provisional US 2006-818910P 20060705; AU 2007307260 A1 AU 2007-307260 20070705; CA 2656531 A1 CA 2007-2656531 20070705; CN 101517074 A CN 2007-80032858 20070705; EP 2046951 A2 EP 2007-861330 20070705; TW 2008017517 A TW 2007-124475 20070705; US 20090123452 A1 US 2007-825627 20070705; EP 2046951 A2 PCT Application WO 2007-US15571 20070705; KR 2009031936 A PCT Application WO

2007-US15571 20070705; NO 2008005408 A PCT Application WO 2007-US15571 20070705; IN 2009CN00541 P4 PCT Application WO 2007-US15571 20070705; CA 2656531 A1 PCT Application WO 2007-US15571 20070705; CN 101517074 A PCT Application WO 2007-US15571 20070705; MX 2008016221 A1 PCT Application WO 2007-US15571 20070705; CA 2656531 A1 PCT Nat. Entry CA 2007-2656531 20081230; MX 2008016221 A1 MX 2008-16221 20081217; NO 2008005408 A NO 2008-5408 20081230; IN 2009CN00541 P4 IN 2009-CN541 20090129; KR 2009031936 A KR 2009-702442 20090205; JP 2009542218 W PCT Application WO 2007-US15571 20070705; JP 2009542218 W JP 2009-518386 20070705

FDT EP 2046951 A2 Based on WO 2008045148 A; KR 2009031936 A Based on WO 2008045148 A; AU 2007307260 A1 Based on WO 2008045148 A; CA 2656531 A1 Based on WO 2008045148 A; CN 101517074 A Based on WO 2008045148 A; MX 2008016221 A1 Based on WO 2008045148 A; JP 2009542218 W Based on WO 2008045148 A

PRAI US 2006-818910P 20060705
US 2006-818804P 20060705
US 2007-825627 20070705
US 2006-818804P 20060705
US 2006-818910P 20060705

L13 ANSWER 8 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2008-F49690 [36] WPIDS
CR 2009-E04174
TI New insulin analog that comprises at least two hydrophobic amino acids substituted with hydrophilic amino acids, within or in close proximity to protease cleavage sites of parent insulin, useful for treating e.g. diabetes
DC B04; D13; D16
IN BALSCHMIDT P; HAVELUND S; HUBALEK F; LAUTRUP-LARSEN I; LUDVIGSEN S; NIELSEN P K; NORGAARD P; RIBEL-MADSEN U; NOERGAARD P
PA (NOVO-C) NOVO NORDISK AS
CYC 122
PIA WO 2008034881 A1 20080327 (200836)* EN 62[2]
TW 2008029600 A 20080716 (200924) ZH
NO 2009001563 A 20090420 (200933) NO
EP 2074141 A1 20090701 (200943) EN
KR 2009071561 A 20090701 (200948) KO
IN 2009DN01825 P1 20090529 (200951) EN
AU 2007298919 A1 20080327 (200952) EN
CN 101541830 A 20090923 (200964) ZH
MX 2009002999 A1 20090430 (200970) ES
ADT WO 2008034881 A1 WO 2007-EP59990 20070920; AU 2007298919 A1 AU 2007-298919 20070920; CN 101541830 A CN 2007-80043130 20070920; EP 2074141 A1 EP 2007-820423 20070920; NO 2009001563 A PCT Application WO 2007-EP59990 20070920; EP 2074141 A1 PCT Application WO 2007-EP59990 20070920; KR 2009071561 A PCT Application WO 2007-EP59990 20070920; IN 2009DN01825 P1 PCT Application WO 2007-EP59990 20070920; CN 101541830 A PCT Application WO 2007-EP59990 20070920; TW 2008029600 A TW 2007-135252 20070921; KR 2009071561 A KR 2009-705790 20070920; IN 2009DN01825 P1 IN 2009-DN1825 20090319; NO 2009001563 A NO 2009-1563 20090420; MX 2009002999 A1 PCT Application WO 2007-EP59990 20070920; MX 2009002999 A1 MX 2009-2999 20090319
FDT EP 2074141 A1 Based on WO 2008034881 A; KR 2009071561 A Based on WO 2008034881 A; AU 2007298919 A1 Based on WO 2008034881 A; CN 101541830 A Based on WO 2008034881 A; MX 2009002999 A1 Based on WO 2008034881 A
PRAI EP 2006-121113 20060922

L13 ANSWER 9 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2008-B71099 [12] WPIDS
CR 2008-B64222

TI New recombinant mammalian precursor protein comprises a protease site for proteolytic cleavage and liberation of mature growth/differentiation factor 5 related protein, useful for preventing or treating neurodegenerative disorders
DC B04; D16
IN PLOEGER F; POHL J; PLOGER F
PA (BIOP-N) BIOPHARM GES BIOTECHNOLOGISCHEN ENTWICKL; (BIOP-N) BIOPHARM GES BIOTECHNOLOGISCHEN ENTWICKLUNGS
CYC 121
PIA WO 2008009419 A1 20080124 (200812)* EN 51
EP 2043674 A1 20090408 (200929) EN
CA 2657349 A1 20080124 (200977) EN
JP 2009543566 W 20091210 (200981) JA 33
ADT WO 2008009419 A1 WO 2007-EP6331 20070717; CA 2657349 A1 CA 2007-2657349 20070717; EP 2043674 A1 EP 2007-786127 20070717; EP 2043674 A1 PCT Application WO 2007-EP6331 20070717; CA 2657349 A1 PCT Application WO 2007-EP6331 20070717; CA 2657349 A1 PCT Nat. Entry CA 2007-2657349 20090109; JP 2009543566 W PCT Application WO 2007-EP6331 20070717; JP 2009543566 W JP 2009-519863 20070717
FDT EP 2043674 A1 Based on WO 2008009419 A; CA 2657349 A1 Based on WO 2008009419 A; JP 2009543566 W Based on WO 2008009419 A
PRAI EP 2006-14928 20060718

L13 ANSWER 10 OF 140 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1272089 HCAPLUS
DN 150:30225
TI An engineered protease that cleaves specifically after sulfated tyrosine
AU Varadarajan, Navin; Georgiou, George; Iverson, Brent L.
CS Departments of Chemical Engineering and Chemistry and Biochemistry, University of Texas, Austin, TX, 78712, USA
SO Angewandte Chemie, International Edition (2008), 47(41), 7861-7863
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 140 MEDLINE on STN DUPLICATE 2
AN 2008615010 MEDLINE
DN PubMed ID: 18710212
TI Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.
AU Sadiq S Kashif; Wright David; Watson Simon J; Zasada Stefan J; Stoica Ileana; Coveney Peter V
CS Centre for Computational Science, Department of Chemistry, University College London, London, WC1H 0AJ, UK.
SO Journal of chemical information and modeling, (2008 Sep) Vol. 48, No. 9, pp. 1909-19. Electronic Publication: 2008-08-19.
Journal code: 101230060. ISSN: 1549-9596.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
LA English
FS Priority Journals
EM 200811
ED Entered STN: 23 Sep 2008
Last Updated on STN: 18 Nov 2008
Entered Medline: 17 Nov 2008

L13 ANSWER 12 OF 140 MEDLINE on STN DUPLICATE 3
AN 2008676424 MEDLINE
DN PubMed ID: 18674574
TI Sapovirus-like particles derived from polyprotein.
AU Hansman Grant S; Oka Tomoichiro; Takeda Naokazu
CS Department of Virology II, National Institute of Infectious Diseases, Japan.. g@nih.go.jp
SO Virus research, (2008 Nov) Vol. 137, No. 2, pp. 261-5. Electronic Publication: 2008-08-15.
Journal code: 8410979. ISSN: 0168-1702.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Priority Journals
EM 200901
ED Entered STN: 23 Oct 2008
Last Updated on STN: 7 Jan 2009
Entered Medline: 6 Jan 2009

L13 ANSWER 13 OF 140 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN DUPLICATE 4
AN 2009033996 EMBASE
TI Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.
AU Chellappan, S.; Reddy, G.S.K.K.; Ali, A.
SO Chemtracts, (March 2008) Vol. 21, No. 3, pp. 103-104.
ISSN: 1431-9268 CODEN: CHEMFW
PB Data Trace Publishing Company, 110 West Road, Ste. 227, Towson, Maryland, MD 21204-2316, United States.
CY United States
DT Journal; Article
FS 004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 6 Feb 2009
Last Updated on STN: 6 Feb 2009

L13 ANSWER 14 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2007-830342 [77] WPIDS
DNC C2007-286430 [77]
TI Novel hepatocyte growth factor HGF precursor protein mutant composed of HGF-alpha-chain or polypeptide region, HGF-beta-chain and peptide chain X, in pharmaceuticals for treating renal disorders, cancer, liver cirrhosis/skin ulcer
DC B04; D16
IN ADACHI K; FUKUTA K; HAYATA D; MATSUMOTO K; NAKAMURA T
PA (OSAU-C) UNIV OSAKA; (KRIN-N) KRINGLE PHARMA INC
CYC 119
PIA WO 2007122975 A1 20071101 (200777)* JA 41[3]
EP 2014676 A1 20090114 (200907) EN
CA 2649800 A1 20071101 (200946) EN
US 20090209463 A1 20090820 (200955) EN
JP 2008512049 X 20090903 (200958) JA 29
ADT WO 2007122975 A1 WO 2007-JP57109 20070330; CA 2649800 A1 CA 2007-2649800 20070330; EP 2014676 A1 EP 2007-740545 20070330; EP 2014676 A1 PCT Application WO 2007-JP57109 20070330; CA 2649800 A1 PCT Application WO 2007-JP57109 20070330; US 20090209463 A1 PCT Application WO 2007-JP57109

20070330; CA 2649800 A1 PCT Nat. Entry CA 2007-2649800 20081020; US 20090209463 A1 US 2009-226448 20090130; JP 2008512049 X PCT Application WO 2007-JP57109 20070330; JP 2008512049 X JP 2008-512049 20070330
FDT EP 2014676 A1 Based on WO 2007122975 A; CA 2649800 A1 Based on WO 2007122975 A; JP 2008512049 X Based on WO 2007122975 A
PRAI JP 2006-116498 20060420

L13 ANSWER 15 OF 140 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
AN 2007-719364 [67] WPIDS
DNC C2007-252308 [67]
TI New coagulation factor X polypeptide with modified activation properties, useful for treating or preventing blood coagulation disorder, e.g. hemophilia
DC B04; D16
IN HAUSER H; KALINA U; SCHULTE S; WEIMER T
PA (CSLB-N) CSL BEHRING GMBH; (ZLBB-N) ZLB BEHRING GMBH; (HAUS-I) HAUSER H; (KALI-I) KALINA U; (SCHU-I) SCHULTE S; (WEIM-I) WEIMER T
CYC 118
PIA WO 2007096116 A1 20070830 (200767)* EN 50[3]
EP 1820508 A1 20070822 (200767) EN
EP 1991255 A1 20081119 (200878) EN
KR 2008107385 A 20081210 (200915) KO
AU 2007218266 A1 20070830 (200922) EN
CA 2642910 A1 20070830 (200938) EN
US 20090175828 A1 20090709 (200945) EN
JP 2009527234 W 20090730 (200950) JA 30
ADT WO 2007096116 A1 WO 2007-EP1417 20070219; EP 1820508 A1 EP 2006-3475 20060221; US 20090175828 A1 Provisional US 2006-780066P 20060308; AU 2007218266 A1 AU 2007-218266 20070219; CA 2642910 A1 CA 2007-2642910 20070219; EP 1991255 A1 EP 2007-722853 20070219; EP 1991255 A1 PCT Application WO 2007-EP1417 20070219; KR 2008107385 A PCT Application WO 2007-EP1417 20070219; CA 2642910 A1 PCT Application WO 2007-EP1417 20070219; US 20090175828 A1 PCT Application WO 2007-EP1417 20070219; CA 2642910 A1 PCT Nat. Entry CA 2007-2642910 20080819; US 20090175828 A1 US 2008-224182 20080820; KR 2008107385 A KR 2008-720484 20080821; JP 2009527234 W PCT Application WO 2007-EP1417 20070219; JP 2009527234 W JP 2008-555681 20070219
FDT EP 1991255 A1 Based on WO 2007096116 A; KR 2008107385 A Based on WO 2007096116 A; AU 2007218266 A1 Based on WO 2007096116 A; CA 2642910 A1 Based on WO 2007096116 A; JP 2009527234 W Based on WO 2007096116 A
PRAI EP 2006-3475 20060221
US 2006-780066P 20060308

=>
<------User Break------>

=> s l13 and review
L14 3 L13 AND REVIEW

=> d l14 1-3 bib ab

L14 ANSWER 1 OF 3 MEDLINE on STN
AN 2003327749 MEDLINE
DN PubMed ID: 12858075
TI An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
AU Yarranton Helen; Machin Samuel J
CS Haemostasis Research Unit, Department of Haematology, University College London, London, UK.

SO Current opinion in neurology, (2003 Jun) Vol. 16, No. 3, pp. 367-73. Ref: 48
Journal code: 9319162. ISSN: 1350-7540.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Priority Journals
EM 200308
ED Entered STN: 15 Jul 2003
Last Updated on STN: 16 Aug 2003
Entered Medline: 15 Aug 2003
AB PURPOSE OF REVIEW: Thrombotic thrombocytopenic purpura, a clinical syndrome characterized by thrombocytopenia and microangiopathic haemolytic anaemia, was almost universally fatal until the introduction of plasma exchange therapy in the 1970s. Current outcomes have improved dramatically with the initiation of prompt plasma exchange, a treatment routinely used without any real understanding of why it is effective. RECENT FINDINGS: Recent advances suggest that a deficiency of a specific plasma metalloprotease, responsible for the physiological processing of von Willebrand factor multimers, plays a substantial role in the pathogenesis of congenital and acquired idiopathic thrombotic thrombocytopenic purpura. The von Willebrand factor-cleaving protease has now been identified as a new member of the ADAMTS family of metalloproteases, designated ADAMTS13. The acquired form of thrombotic thrombocytopenic purpura is associated with inhibitory autoantibodies against ADAMTS13, and the congenital chronic relapsing form is caused by mutations in the ADAMTS13 gene, resulting in a constitutional deficiency. Plasma exchange has been proved to be the most important therapy in thrombotic thrombocytopenic purpura, but clinical data for adjunctive therapies, such as corticosteroids, antiplatelet drugs and other immunosuppressive agents often used in combination with plasma exchange, are less well defined. SUMMARY: Recent advances in our understanding of the pathological mechanisms of thrombotic thrombocytopenic purpura not only provide a rationale for the previously empirical plasma exchange therapy (removal of the inhibitory antibodies and replacement of the deficient protease from the plasma infused), but may also help in developing more rational and targeted treatment strategies. This review discusses the clinical presentation, pathophysiology and current management of thrombotic thrombocytopenic purpura.

L14 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:294313 HCAPLUS
DN 139:50682
TI TTP and ADAMTS13 mutation
AU Fujimura, Yoshihiro
CS Affiliated Hospital, Nara Prefectural Medical University, Japan
SO Annual Review Ketsueki (2003) 153-162
CODEN: ARKNB7
PB Chugai Igakusha
DT Journal; General Review
LA Japanese
AB A review on von Willebrand factor (vWF) cleaving protease ADAMTS13 mutation in thrombotic thrombocytopenic purpura (TTP). The topics discussed are (1) unusually large vWF multimers in TTP; (2) vWF cleaving protease activity and its IgG type inhibitor; (3) TTP vs. Upshaw-Schulman syndrome; and (4) von Willebrand factor cleaving protease ADAMTS13 and its mutation in TTP.

L14 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
AN 1987:82679 HCAPLUS
DN 106:82679
OREF 106:13549a,13552a
TI Cleavage site mutant as a potential vaccine
AU Homma, Morio
CS Sch. Med., Kobe Univ., Kobe, 650, Japan
SO Concepts Viral Pathog. (1986), Volume 2, 388-93. Editor(s): Notkins, Abner Louis; Oldstone, Michael B. A. Publisher: Springer, New York, N. Y. CODEN: 52MXA4
DT Conference; General Review
LA English
AB A review with 21 refs. Paramyxoviruses and influenza viruses become activated and replicate in multiple cycles when the envelope glycoprotein of the virus is cleaved by a host protease . In the absence of protease, the replication is limited to a single cycle. A protease activation mutant of Sendai virus was obtained, whose replication is restricted to a single cycle in the lung of mice, but which nevertheless, induces immunity. The availability of such mutants for vaccines, their strengths and limitations are discussed.